Unraveling the relationship between autoimmune pancreatitis type 2 and inflammatory bowel disease: Results from two centers and systematic review of the literature

Sara Nikolic1,2 | Marco Lanzillotta3,4 | Nikola Panic5 | Torkel B. Brismar6 | Carlos Fernández Moro7 | Gabriele Capurso8 | Emanuel Della Torre3,4 | J.-Matthias Löhr9,10 | Miroslav Vujasinovic1,9

1Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden
2Department of Gastroenterology, Clinic for Internal Medicine, University Medical Centre Maribor, Maribor, Slovenia
3Università Vita-Salute San Raffaele, IRCCS San Raffaele Scientific Institute, Milan, Italy
4Unit of Immunology, Rheumatology, Allergy and Rare Diseases (Unirar), IRCCS San Raffaele Scientific Institute, ss Milan, Milan, Italy
5Faculty of Medicine, University of Belgrade, Digestive Endoscopy Unit, University Clinic “Dr Dragisa Misovic”, Belgrade, Serbia
6Department of Radiology, Karolinska University Hospital, Stockholm, Sweden
7Department of Clinical Pathology and Cancer Diagnostics, Karolinska University Hospital, Stockholm, Sweden
8Division of Pancreatic Surgery and Endosonography Division, Pancreas Translational and Clinical Research Center, IRCCS San Raffaele Scientific Institute, Milan, Italy
9Department of Upper Digestive Diseases, Karolinska University Hospital, Stockholm, Sweden
10Department of Clinical Science, Intervention, and Technology (CLINTEC), Karolinska Institutet, Stockholm, Sweden

Abstract

Introduction: The relationship between autoimmune pancreatitis (AIP) type 2 and inflammatory bowel disease (IBD) has been established and previously described within International Consensus Diagnostic Criteria. However, it is unknown if the presence of IBD changes the natural disease course of AIP type 2. Our aim was to investigate the association between AIP type 2 and IBD as well as to systematically summarize all the existing evidence in the literature.

Methods: Electronic medical record analysis was conducted in two centers (in Stockholm, Sweden, and Milan, Italy; records dated between January 2001 and June 2021). Additionally, we conducted a systematic review of the literature.

Results: A total of 35 patients (18 females, 51.4%) fulfilled the diagnostic criteria of AIP type 2 and were included in the study. A diagnosis of IBD was established in 29 patients (54.5%). The presence of IBD was associated with a shorter time to AIP diagnosis, lower pre-AIP serum elastase-1 levels, and a higher rate of pancreatic cancer. Interestingly, the presence of IBD did not affect the rate of AIP relapse or the need for immunosuppression.

Abbreviations: AIP, autoimmune pancreatitis; AP, acute pancreatitis; AZA, azathioprine; CD, Crohn’s disease; DM, diabetes mellitus; FEI, fecal elastase-1; GC, glucocorticoids; HR, hazard ratio; IBD, inflammatory bowel disease; ICDC, International Consensus Diagnostic Criteria; L, interleukin; OOI, other organ involvement; PEI, pancreatic exocrine insufficiency; TNF, tumor necrosis factor; UC, ulcerative colitis.

Sara Nikolic and Marco Lanzillotta share first authorship.
J.-Matthias Löhr and Miroslav Vujasinovic share senior authorship.
All authors approved the final version of the article, including the authorship list.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2022 The Authors. United European Gastroenterology Journal published by Wiley Periodicals LLC on behalf of United European Gastroenterology.
patients (82.8%), ulcerative colitis in 17 (58.6%) and Crohn’s disease in 11 (37.9%). Median follow-up was 54 months. AIP patients with IBD commonly presented with abdominal pain and/or acute pancreatitis at diagnosis, the latter was prevailing in concomitant and later IBD onset. These patients more frequently used steroids, but there were no differences in relapse rates. Concomitant onset of IBD was associated with the development of diabetes mellitus. There were no cases of colon or pancreatic malignancy during follow-up. In our systematic analysis, a total of 693 AIP type 2 patients were included from 24 single-center retrospective studies and 8 multicenter retrospective studies. A diagnosis of IBD was reported in 330 (47.8%) patients. Relapse rate was 20.0%.

**Conclusions:** Clinical and radiological remission of AIP type 2 was high, while the cumulative incidence of relapse is around 20%. Our results show that concomitance of IBD imposes no obvious risk of a different disease course for AIP type 2.

**KEYWORDS**
autoimmune, inflammatory bowel disease, pancreatitis, systematic review

**INTRODUCTION**

Autoimmune pancreatitis (AIP) is a unique form of pancreatic inflammation that often causes chronic pancreatitis with consequent pancreatic exocrine insufficiency (PEI) and endocrine insufficiency. To date, histopathological observations have identified two AIP subtypes: lymphoplasmacytic sclerosing pancreatitis, also called AIP type 1, and idiopathic duct-centric chronic pancreatitis, or AIP type 2. The former belongs to the IgG4-related disease spectrum, being its most prevalent manifestation in the digestive system, characterized by fibrotic lesions rich in IgG4 + plasma cells. Hence, multiple other organ involvement (OOI), positive IgG4 serology in the majority of patients and a significant relapse rate after treatment are typical AIP type 1 features. In contrast, AIP type 2 is less frequent, unrelated to IgG4 and associated with a lower risk of relapse after treatment. Involvement of organs typically described in type I AIP is not observed in AIP type 2, where inflammatory bowel diseases (IBD) are more commonly described and acknowledged within the International Consensus Diagnostic Criteria (ICDC). Indeed, the presence of IBD in patients with imaging evidence for AIP suggests a probable AIP type 2 diagnosis. Definite AIP type 2 diagnosis still requires either histologically confirmed idiopathic duct-centric pancreatitis or the presence of IBD and positive glucocorticoid (GC) trial.

Overlooking a diagnosis of IBD in the setting of AIP-type-2-associated pancreatic exocrine insufficiency may not be infrequent as both diseases can present with diarrhea and abdominal discomfort. Moreover, there is a certain amount of similarity and overlap between both initial IBD and AIP treatment (GC, azathioprine), so the choice of AIP treatment might be influenced by the synchronous IBD, and vice versa. More importantly, IBD concurrent with AIP might hypothetically lead to a broadening of the available treatment options since a recent report described the successful use of tumor necrosis factor (TNF) inhibitors in AIP type 2 patients with and without concomitant IBD.

While the prevalence of IBD in different types of pancreatitis and the influence of AIP on the natural disease course of IBD have been described before, whether the presence of IBD influences the

**Key summary**

**Summarise the established knowledge on this subject**
- The relationship between autoimmune pancreatitis (AIP) type 2 and inflammatory bowel disease (IBD) has been established and previously described within International Consensus Diagnostic Criteria.
- It is unknown if the presence of IBD changes the natural disease course of AIP type 2.
- Our aim was to investigate the association between AIP type 2 and IBD as well as to systematically summarize all the existing evidence in the literature.

**What are the significant and/or new findings of this study?**
- Clinical and radiological remission of AIP type 2 was high, while the cumulative incidence of relapse is around 20%.
- Our results show that concomitance of IBD imposes no obvious risk of a different disease course for AIP type 2.
- However, AIP should be considered as a differential diagnosis in patients with IBD presenting with gastrointestinal complaints unexplained by the underlying bowel disorder.
Exposure was defined as the diagnosis of IBD according to the European Crohn’s and Colitis Organization (ECCO) and the European Society of Gastrointestinal and Abdominal Radiology (ESGAR) joint collaborative guidelines. Exposure was classified in a sub-analysis according to IBD onset in relation to AIP. IBD in relation to the date of AIP diagnosis was subclassified as: before AIP diagnosis (IBDb), IBD concomitant (maximum 2 months diagnostic delay) with AIP (IBDC), and IBD after AIP diagnosis (IBDa). The outcome was treatment efficacy in terms of AIP remission and relapse. Relapse was defined as the recurrence of clinical and/or radiological features consistent with AIP type 2 after the first-line treatment. Remission was defined as the normalization of clinical and/or clinical abnormalities. Clinical remission without maintenance treatment was defined as the absence of both IBD and AIP-related systematic treatments (GC, azathioprine (AZA), infliximab, adalimumab, ustekinumab, golimumab, vedolizumab, budesonide, rituximab). Pancreatic exocrine function (using fecal elastase 1 = FE1) and endocrine function (presence of diabetes mellitus (DM)) at last follow-up was also recorded.

At the baseline, we retrieved data regarding age at diagnosis of AIP, gender, symptoms at the time of AIP diagnosis (asymptomatic, new onset diabetes, acute pancreatitis, obstructive jaundice, weight loss, abdominal pain), OOI and pancreatic insufficiency in terms of endocrine dysfunction and exocrine dysfunction. Information related to AIP and IBD treatment was retrieved, as well as surgical procedures.

Data related to IBD was also collected, including the subtype (ulcerative colitis (UC), Crohn’s disease (CD), indeterminate colitis), the onset of diagnosis in relation to AIP diagnosis (before, concomitant, after) and the treatment. The extent of colonic inflammation in UC, as well as the localization and behavior of the CD, were described according to Montreal classification.

Ethics

The study adhered to the latest version of the Declaration of Helsinki and was approved by both the Clinic Ethical Committee in Stockholm, Sweden (Dnr. 2016/1571-31 and 2020-02209) and the Ethical Committee in Milan, Italy (22/INT/2018).

Statistical analysis

Data is expressed as median and interquartile range (IQR) for numerical data, or percentages for categorical data. The comparison of data was undertaken using appropriate non-parametric statistical tests, for categorical data the chi-square or Fisher’s exact test, for numerical data the Mann-Whitney U test or Kruskal-Wallis test. Univariable and multivariable analyses were performed to identify possible predictors for relapse, based on a Cox-proportional hazards regression model. Hazard ratios (HR) were expressed with 95% confidence intervals (CI 95%). The analysis was performed using IBM SPSS Statistics 28. A p-value <0.05 (two-sided) was considered statistically significant.
Systematic review of the literature

Search strategy and study selection

A literature search following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines was conducted to identify all relevant original articles referring to the relation between type 2 AIP and IBD. Cochrane, Embase, Google Scholar, PubMed and Web of Science databases were searched from 2003 until 15 August 2021 using the following search terms (‘autoimmune pancreatitis’ OR ‘autoimmune pancreatitis type 2’) AND (‘inflammatory bowel disease’ OR ‘ulcerative colitis’ OR ‘Crohn’s Disease’). Prisma checklist is presented in Table S1 and search strategy in Table S2. Eligibility assessment was performed by screening the titles and, subsequently, the abstracts and full articles. This was undertaken by three independent reviewers (SN, ML, NP). All disagreements were resolved by MV and JML. Review articles, editorials, conference reports, comments on other studies, animal studies, non-English-language articles, book sections and theses, overlapping articles and articles that did not contain individual data on the prevalence of IBD in patients with AIP type 2 were excluded. When the results of a single study were reported in more than one publication, only the most recent or complete data was included in the analysis. Using a “snowball method”, additional articles were identified by hand-searching the reference lists of all the articles retrieved to identify potentially relevant studies. The same above-mentioned inclusion criteria were then applied. Studies in which a distinction between AIP type 1 and type 2 was not made were excluded. The proportions of patients having IBD subtypes, definite AIP diagnosis and certain treatment options were calculated by referring to the total number of patients in the respective study. The quality of the studies was assessed according to a checklist based on a modified version of the Newcastle–Ottawa quality assessment scale, with a score ranging 0–9. The selection process of articles for the review is summarized in Figure 2.

RESULTS

Baseline characteristics of patients with AIP

In total, 35 patients (18 females, 51.4%) fulfilled the diagnostic criteria of AIP type 2 and were included in the study. Baseline demographic and clinical features are reported in Table 1. Twenty-two patients (62.9%) received a definite AIP type 2 diagnosis, while 13 (37.1%) had probable AIP type 2 according to ICDC. The median age at diagnosis was 41 years (IQR 26). The clinical presentation included abdominal pain (30 patients, 85.7%), acute pancreatitis (16 patients, 45.7%), weight loss (7 patients, 20.0%), jaundice (4 patients, 11.4%) and new-onset diabetes (2 patients, 5.6%). Of note, in 2 of the 5 (14.3%) asymptomatic patients, the diagnosis of type 2 AIP had been considered incidental as it was...
unveiled during imaging workup after IBD diagnosis. Median follow-up time for AIP was 54 months (IQR 46.5 months). Two patients were excluded from the long-term analysis because of a short follow-up time (<6 months).

### Characteristics of AIP patients in relation to IBD

A diagnosis of IBD was established in 29 patients (82.8%). UC and CD were diagnosed in 17 (58.6%) and 11 (37.9%) patients, respectively.

#### TABLE 1

Baseline characteristics of autoimmune pancreatitis (AIP) type 2 patients in relation to inflammatory bowel diseases (IBD)

| Patients | Total | IBD |
|----------|-------|-----|
| n = 35 | YES (n = 29, 83%) | NO (n = 6, 17%) |
| Female, n (%) | 18 (51.4) | 14 (48.3) | 4 (66.7%) |
| Age at AIP diagnosis (median, IQR) | 41, 26 | 38.0, 24.0 | 60.0, 35.0 |
| Follow-up (months)* (median, IQR) | 54, 46.5 | 54.0, 47.0 | 61.5, 77.0 |
| Definite AIP 2, n (%) | 22 (62.9) | 16 (55.2) | 6 (100.0) |
| Alcohol consumption >5 U | 1 (2.9) | 1 (3.6) | 0 |
| Smoker |
| Never | 18 (51.4) | 17 (58.6) | 1 (16.7) |
| Former | 14 (40.0) | 11 (37.9) | 3 (50.0) |
| Active | 3 (8.6) | 1 (3.4) | 2 (33.3) |
| Diagnosis by histology, n (%) | 8 (22.9) | 3 (10.3) | 5 (83.3) |
| AIP symptoms at diagnosis, n (%) |
| Abdominal pain | 30 (85.7) | 27 (93.1) | 3 (50.0) |
| Weight loss | 7 (20.0) | 6 (20.7) | 1 (16.7) |
| Acute pancreatitis | 16 (45.7) | 15 (51.7) | 1 (16.7) |
| Jaundice | 4 (11.4) | 2 (6.9) | 2 (33.3) |
| New onset diabetes | 2 (5.7) | 1 (3.4) | 1 (16.7) |
| Incidental finding | 5 (14.3) | 3 (10.3) | 2 (33.3) |
| PEI, n (%) |
| At diagnosis | 11 (31.4) | 10 (34.5) | 1 (16.7) |
| FE-1 (μg/g, median, IQR) | 225.3 | 220.2 | 500.3 |
| At follow-up* | 10 (30.3) | 8 (29.6) | 2 (33.3) |
| FE-1 (μg/g, median, IQR)* | 260.3 | 231.3 | 292.2 |
| Diabetes mellitus, n (%) |
| At diagnosis | 4 (11.4) | 2 (6.9) | 2 (33.3) |
| At follow-up* | 7 (21.2) | 5 (18.5) | 2 (33.3) |
| AIP treatment, n (%) |
| Surgery | 7 (20.0) | 2 (6.9) | 5 (83.3) |
| Steroids | 26 (74.3) | 25 (86.2) | 1 (16.7) |
| Azathioprine | 8 (22.9) | 8 (27.6) | 0 |
| AIP relapse, n (%)* | 8 (24.2) | 7 (25.9) | 1 (17.7) |
| AIP maintenance treatment | 4 (12.1) | 4 (14.8) | 0 |
| Clinical remission at last contact* | 33 (100.0) | 27 (100.0) | 6 (100.0) |
| Clinical remission without systemic therapy for both IBD and AIP | 22 (66.7) | 16 (59.3) | 6 (100.0) |
| Radiological remission at last contact* | 31 (93.9) | 25 (92.6) | 6 (100%) |

Note: (normal >200 μg/g; measured up to 800 μg/g). For variables with *, n = 33.

Abbreviations: AIP, autoimmune pancreatitis; CD, Crohn’s disease; DM, diabetes mellitus; FE-1, fecal elastase-1; IBD, inflammatory bowel disease; IQR, interquartile range; PEI, pancreatic exocrine insufficiency; UC, ulcerative colitis.
In one patient (3.5%), the subtype could not be established. The Montreal classification of the 29 IBD patients is shown in the Table S3. Most of the UC patients had left side colitis. All CD patients had a non-stricturing, non-penetrating disease. IBD was diagnosed after AIP in 10 (34.5%) patients (IBDa patients), while 13 (44.8%) patients received an IBD diagnosis before AIP onset (IBDb patients). In 6 (20.7%) patients, IBD and AIP were diagnosed concomitantly (IBDc patients). AIP patients with IBD showed a trend toward lower median age compared to AIP without IBD (38.0 vs. 60.0 years, p = 0.06). AIP patients with IBD presented significantly more often with abdominal pain (27/29 (93.1%) versus 3/6 (50.0%), p = 0.02). The rate of abdominal pain in the three IBD subgroups (IBDa, IBDb, IBDc) was not statistically different (Table 2). On the other hand, acute pancreatitis as initial presentation of AIP type 2 was more prevalent in patients with IBDc and IBDa compared to IBDb: 5 (83.3%), 7 (70.0%), and 3 (23.1%), respectively (p = 0.02).

### Treatment

In our cohort, 26 (74.3%) patients with AIP type 2 received treatment with GC. GC were used more frequently in AIP patients with IBD (25 patients, 86.2%) compared to those without IBD (1 patient, 16.7%, p < 0.002). A representative example of the clinical effect of steroid treatment is shown in Figure 3. AZA was used to treat AIP only in patients with IBD (8 patients, 22.9%). Seven patients (20.0%) underwent a surgical procedure because a pancreatic malignancy could not be excluded based on clinical and radiological findings. The diagnosis of AIP in these 7 patients was established subsequently by histology according to the ICDC criteria. It is of note that the diagnosis of IBD was made in only one patient at the time of surgery. One patient developed CD 2 years after surgery, while the other 5 patients had no IBD. A watchful waiting approach was chosen in 2 (5.2%) patients due to spontaneous regression of AIP.

### Remission and relapse

At the last contact, all AIP patients (33/33, 100%) were in clinical remission and 31/33 (93.9%) had achieved radiological remission as well. AIP-related maintenance therapy was indicated in 4/33 patients (12.1%). Relapse of AIP occurred in 8/33 (24.2%) patients. The only parameter associated with AIP relapse at the univariate analysis was age at diagnosis. In particular, higher the age, the lower appeared the

### Table 2: Sub-analysis of autoimmune pancreatitis (AIP) type 2 patient characteristics with inflammatory bowel diseases (IBD)

| Total (29 patients) | IBDb (N = 13, 44.8%) | IBDc (N = 6, 20.7%) | IBDa (N = 10, 34.5%) |
|---------------------|----------------------|---------------------|----------------------|
| Female, n (%)       | 7 (53.8)             | 4 (66.7)            | 3 (30.0)             |
| CD, n (%)           | 4 (30.8)             | 2 (33.3)            | 5 (50.0)             |
| UC, n (%)           | 9 (69.2)             | 3 (50.0)            | 5 (50.0)             |
| Age at AIP diagnosis (median, IQR) | 43, 23.0 | 36.0, 27.0 | 31.5, 28.0 |
| Follow-up AIP (months)* (median, IQR) | 52, 47 | 54, 55 | 49, 35 |
| Abdominal pain      | 12 (92.3)            | 5 (83.3)            | 10 (100.0)           |
| Acute pancreatitis  | 3 (23.1)             | 5 (83.3)            | 7 (70.0)             |
| Weight loss         | 1 (7.7)              | 0                   | 5 (50.0)             |
| PEI, n (%)          |                      |                     |                     |
| at diagnosis        | 4 (30.8)             | 5 (83.3)            | 1 (10.0)             |
| at last contact*    | 4 (33.3)             | 2 (40.0)            | 2 (20.0)             |
| Diabetes n (%)      |                      |                     |                     |
| at diagnosis        | 1 (7.7)              | 1 (16.7)            | 0                    |
| at last contact*    | 1 (8.3)              | 4 (80.0)            | 0                    |
| Treatment of AIP, n (%) |                |                     |                     |
| Steroid             | 9 (69.2)             | 6 (100.0)           | 10 (100.0)           |
| Azathioprine        | 5 (38.5)             | 2 (33.3)            | 1 (10.0)             |
| Relapses of AIP n (%)* | 4 (33.3) | 1 (20.0) | 2 (20.0) |
| Clinical remission of AIP without systemic treatment for both AIP and IBD | 6 (50.0) | 2 (40.0) | 8 (80.0) |

Note: For variables with *, N = 33.

Abbreviations: AIP, autoimmune pancreatitis; CD, Crohn's disease; DM, diabetes mellitus; IBD-inflamatory bowel disease; IQR-interquartile range; PEI-pancreatic exocrine insufficiency; UC-ulcerative colitis.
risk of relapse, yet accounting for a very low HR (HR = 0.01 95% CI = 0.02 to -0.001, p = 0.04). Sub-analysis according to IBD onset in AIP patients showed no differences in the above-mentioned outcomes.

**Long-term consequences**

At diagnosis, 11 (31.4%) patients displayed PEI and 4 (11.4%) had DM. At last contact, 10/33 (30.3%) had PEI and 7/33 (21.2%) patients had DM. Interestingly, IBDC patients presented with a higher prevalence of PEI at diagnosis (Table 2). However, no differences in PEI prevalence were recorded at follow-up analysis. On the other hand, in the subgroup of IBDC patients, DM prevalence was significantly higher compared to the IBDb and IBDa groups – 4/5 (80%) versus 1/12 (8.3%) and 0/10 respectively, p = 0.001.

One patient without IBD developed malignant melanoma, while no pancreatic or colorectal cancer were detected during the follow-up.

**Systematic review**

Study selection

Our primary search identified 260 titles. After the removal of duplicate articles, 178 studies remained. We excluded 103 articles because they were not consistent with our inclusion criteria. Finally, 75 studies were included in a qualitative synthesis and the full text of each one was reviewed to establish eligibility for quantitative analysis. After reviewing these articles, 43 more were excluded due to insufficient data related to IBD or AIP subtype. Thirty-two studies fulfilled the inclusion criteria and were selected for the systematic review (Figure 2). The characteristics and key findings of the included studies are reported in (Table S4).

**Results of the individual studies**

Our analysis included 24 single-center retrospective studies and 8 multicenter retrospective studies, with a total of 693 AIP type 2 patients. Among the single-center studies, 14 were performed in Europe, 4 in the USA, 9 in Asian countries and one in Australia. All relevant data that was possible to extract from systematic review studies are presented in the (Table S5).

A diagnosis of IBD was reported in 330 (47.8%) patients, being UC, CD or not assessed in 183 (27.3%), 53 (7.9%), and 94 (14.0%) cases, respectively. In 6 studies, the IBD subtype was not reported. The type of AIP diagnosis was reported in 6 studies, including a total of 147 patients.13,18–22 Among these, a definite AIP type 2 diagnosis was established in 56 (38.0%) patients, a probable type 2 AIP diagnosis in 81 (55.1%) and in 10 (6.8%) the type was not known because the diagnosis of probable AIP type 2 was not established until 2011. Twelve studies (249 patients) reported the timing of both AIP and IBD diagnosis.5,10,13,14,18–20,22–26 AIP type 2 was diagnosed before IBD in 35 (14.0%) cases. AIP clinical presentation was mentioned in 12 reports (227 patients)5,10,13,18,19,21,22,24,25,27–29 Acute pancreatitis was the initial manifestation in 105 patients (46.2%) and jaundice in 19 (8.4%). AIP treatment was reported in 16 studies (316 patients).13,14,18–20,22–25,27–33 Surgery was performed in 91 patients (28.8%), while systemic steroids were used in 94 patients (29.7%). A watchful waiting strategy was used in 49 patients (15.5%). A total of 40 (20.2%) AIP relapses were recorded in 9 studies (198 patients).14,18,20–22,25,27,30,31 IBD treatment was reported in 8 articles (180 patients).13,14,18,22–25,33 Topical treatment, GC, standard therapy (azathioprine, methotrexate), and TNF-inhibitors were used in 70 patients (38.8%), 15 patients (8.3%), 59 patients (32.8%) and 48 (26.7%) patients, respectively. Unfortunately, due to insufficient data, it was not possible to compare characteristics or outcomes between type 2 AIP patients with and without IBD.
DISCUSSION

AIP type 2 is a specific entity within the pancreatic diseases spectrum.\textsuperscript{34} In this work, we aimed to examine the salient features in AIP type 2 patients from a large dual-center cohort, with a special focus on the relationship with IBD occurrence. The existing evidence in the literature on this subject was also systematically evaluated.

The prevalence of IBD in our study was 82.8%, whereas the systematic review analysis reveals a prevalence of 47.8%. This discrepancy can be explained by significant heterogeneity among the selected studies, including different sample sizes (2–89 patients) and a wide range of reported IBD prevalence (10.4%–100%).\textsuperscript{10,11,13,14,18–33,36–47} Interestingly, AIP patients with IBD in our cohort were more likely to have a definite diagnosis compared with studies included in the systematic review, 55% versus 38.0% respectively.\textsuperscript{13,20–22,42} In line with the observations of the systematic review, the ratio of UC to CD in our study was 3:1.\textsuperscript{10,11,13,14,18–33,36–47} Moreover, the location and behavior of the CD according to the Montreal classification\textsuperscript{22} were similar to the results reported by Lorenzo et al.,\textsuperscript{22} with predominantly non-stricturing, non-penetrating disease, located mainly in the colon. The location of UC was predominantly the left colon (Table S1).

AIP patients with IBD were more likely to have acute pancreatitis (not statistically significant) and abdominal pain at presentation. The prevalence of acute pancreatitis in our cohort was similar to that identified from the systematic review of the literature, 45.2% versus 45.7%.\textsuperscript{10,13,14,18–20,22,24,25,27–29,48} Hart et al.\textsuperscript{24} observed a higher prevalence of acute pancreatitis in patients with concurrent IBD, which was also the case in our cohort (Table 1), but the difference was not statistically significant in our study. Moreover, AIP patients with either IBDC or IBDA were more likely to present with acute pancreatitis (Table 2). Interestingly, IBDA patients complained about weight loss significantly more often than those in the IBDC or IBDb groups. Thus, it may be important to consider the concomitant presence of IBD and AIP in patients with non-typical clinical course.

In contrast to the findings of the systematic review, in our study GC treatment was the most prevalent therapy choice (74.3% vs. 29.2%), in comparison to surgery (20% vs. 28.8%) and watchful waiting (11.4% vs. 15.5%).\textsuperscript{1,13,14,18–20,22,23,25,27,28,30–33,40,42} This observation is probably due to the generally higher proportion of IBD in our cohort. Consequently, surgery was significantly more prevalent as a treatment method in AIP type 2 patients without IBD, while steroids were used in AIP type 2 patients with IBD. We noted a trend towards a significant association between the onset of IBD and GC treatment for AIP in the IBDC and IBDA groups. The use of AZA is commonly considered in the setting of both AIP and IBD-related maintenance therapy. Yet, the risk of AZA-induced acute pancreatitis is significant, occurring in up to 7% of AZA-exposed patients.\textsuperscript{49}

Biologic drugs, including TNF inhibitors, form a central part of the IBD armamentarium. Recently, Lorenzo et al.\textsuperscript{10} have reported the successful use of adalimumab in the induction of remission in a patient with AIP type 2 in the absence of concomitant IBD. In addition, the authors treated three patients with active IBD and relapsing AIP with TNF inhibitors, achieving remission of the pancreatic disease. Indeed, granulocyte epithelial lesions are central in AIP type 2 diagnosis\textsuperscript{19,50} and reflect an extensive neutrophil infiltration within the pancreatic parenchyma. As a result of neutrophilic chemotactic power, the overexpression of interleukin (IL) 8 was associated with both AIP type 2 (in ducts) and UC (in crypt epithelium).\textsuperscript{27} This evidence suggests a putative common pathogenetic pathway. Given these data, it is reasonable to speculate that a common treatment strategy might be effective for both diseases. From this perspective, recent findings on the use of colchicine to target neutrophils in AIP type 2 are of interest and deserve further investigation in patients with concomitant IBD.\textsuperscript{51}

In our study, a high proportion of AIP type 2 patients achieved clinical and radiological remission without AIP-related maintenance treatment (2/3 of the patients had neither AIP nor IBD-related systemic treatment). The cumulative incidence of relapse during median follow-up of 54 months was in line with the average 20% relapse in the analyzed literature where information on relapse was available.\textsuperscript{14,21,22,25,27,28} Moreover, a low relapse rate in AIP type 2 in comparison to AIP type 1 has been noticed before.\textsuperscript{52} In contrast to what is known about other organ involvement as a predictor of relapse in AIP type 1,\textsuperscript{53,54} according to our results, AIP type 2 patients with IBD are not at higher risk of relapse in comparison to AIP type 2 patients without IBD. In fact, the onset of IBD did not seem to influence the remission or relapse rates. Nevertheless, more prospective studies should be performed to validate this assumption.

We observed a significantly higher prevalence of PEI at diagnosis in IBDC patients.\textsuperscript{55} At last contact with patients, that difference was no longer significant due to PEI recovery in 3 patients. This might be explained by the dilution effect of diarrhea on fecal elastase-1 (FE1) concentration that is, falsely low FE1 values.\textsuperscript{56} Interestingly, the opposite was observed in DM prevalence—it was significantly higher at the last contact. We believe that it is crucial to regard IBD as a reason for malabsorption syndrome and diarrhea in AIP patients, and especially vice versa. The risk of cancer seems to be low, as we detected no pancreatic or colon cancer during follow-up.

Our work does not come without limitations. Besides the obvious—small sample size due to AIP type 2 being an orphan disease—the retrospective nature of the study might have affected data retrieval. Also, AIP type 2 awareness has changed over time, thus artificially modifying the temporal relationship with IBD, as previous AIP might have been overlooked and the diagnosis delayed. On the other hand, nowadays, AIP type 2 patients without IBD might be at risk of being underdiagnosed, potentially introducing a certain selection bias. Findings found from the comparison of AIP type 2 patients with and without IBD should be interpreted with caution due to the low number of patients without IBD. Since both our centers are tertiary, some referral bias might be present. Moreover, IBD treatment strategies might have reflected different local policies. For example, treatment with biologics was more common in Stockholm compared to Milan. Systematic review was not registered in the PROSPERO database which is a limitation of the study.
Despite these limitations, our work is based on the cohorts of two centers highly skilled in the management of pancreatic diseases. According to the systematic review we performed, this is the first paper exploring the influence of IBD on AIP-related outcomes.

In conclusion, there was no obvious association between IBD and relapse or remission in AIP type 2. The prevalence of both clinical and radiological remission was very high, while the cumulative incidence of relapse was around 20%. Remarkably, IBD represents a common bystander that should be actively investigated and managed in a multidisciplinary approach. However, IBD does not seem to be a risk factor for a more aggressive AIP type 2 natural course. Potentially common pathogenetic pathways and effective treatment strategies for both diseases should be explored in further studies.

ACKNOWLEDGEMENTS
We thank our colleague Charlotte Hedin, MD, PhD Karolinska Institutet, Department of Medicine Solna, Stockholm, Sweden, for her valuable comments and help in the preparation of the manuscript.

We also thank the Swedish Society for Development of Pancreatology (SveSuP) for continuous support, promotion and creating awareness of pancreas diseases in Swedish society.

This article is part of Sara Nikolic’s PhD thesis.

Miroslav Vujasinovic is supported by the Swedish Magtarmfondens stipendium for research and Ruth and Richard Julin Foundation for research (not related to the present study). Nikola Panic was supported by a mobility grant from the European Pancreatic Club. Sara Nikolic is supported by Pancreas 2000—an educational program for future pancreatologists.

CONFLICT OF INTEREST
Miroslav Vujasinovic: Abbott (lecture fee), Mylan (lecture fee); Sara Nikolic: Ferring (lecture fee), Mylan (lecture fee), Krka (lecture fee); J.-Matthias Löhr: Abbott (lecture fee), Mylan (lecture fee).

AUTHOR CONTRIBUTIONS
Study conception and design: Sara Nikolic, Marco Lanzillotta, Miroslav Vujasinovic. Acquisition of data: Sara Nikolic, Marco Lanzillotta, Miroslav Vujasinovic. Statistical analysis: Sara Nikolic, Marco Lanzillotta; Interpretation of data and drafting of the manuscript: all authors.

DATA AVAILABILITY STATEMENT
Research data are not shared.

ORCID
Sara Nikolic https://orcid.org/0000-0003-3751-2619
Marco Lanzillotta https://orcid.org/0000-0002-4522-2921
Nikola Panic https://orcid.org/0000-0002-5930-9884
Torkel B. Brismar https://orcid.org/0000-0002-3409-1938
Carlos Fernández Moro https://orcid.org/0000-0001-6863-5959
Gabriele Capurso https://orcid.org/0000-0002-0019-8753
Emanuel Della Torre https://orcid.org/0000-0002-9192-4270
J.-Matthias Löhr https://orcid.org/0000-0002-7647-198X
Miroslav Vujasinovic https://orcid.org/0000-0002-6496-295X

REFERENCES
1. Hart PA, Krishna SG, Okazaki K. Diagnosis and management of autoimmune pancreatitis. Curr Treat Options Gastroenterol. 2017;15(4):538–47. https://doi.org/10.1007/s11938-017-0147-x
2. Löhr JM, Beuers U, Vujasinovic M, Alvaro D, Frejkjar JB, Buttgereit F, et al. European Guideline on IgG4-related digestive disease: UEG and SFG evidence-based recommendations. United Eur Gastroenterol J. 2020;8(6):637–66. https://doi.org/10.1177/2050646020934911
3. Shimosegawa T, Chari ST, Frulloni L, Kamisawa T, Kawa S, Mino-Kenudson M, et al. International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology. Pancreas. 2011;40(3):325–8. https://doi.org/10.1097/MPA.0b013e3182142fd2
4. Löhr JM, Vujasinovic M, Rosendahl J, Stone JH, Beuers U. IgG4-related diseases of the digestive tract. Nat Rev Gastroenterol Hepatol. 2021;19(3):185–97. https://doi.org/10.1038/s41575-021-00529-y
5. de Pretis N, Frulloni L. Autoimmune pancreatitis type 2. Curr Opin Gastroenterol. 2020;36(5):417–20. https://doi.org/10.1097/MOG.0000000000000655
6. Zen Y Type 2 autoimmune pancreatitis: consensus and controversies. Gut and Liver. 2021. https://doi.org/10.5009/gnl210241
7. Aziz I, Simrén M. The overlap between irritable bowel syndrome and organic gastrointestinal diseases. Lancet Gastroenterol Hepatol. 2021;6(2):139–48. https://doi.org/10.1016/s2468-1253(20)30212-0
8. Raine T, Bonovas S, Burisch J, Kucharzik T, Adamina M, Annese V, et al. ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohn’s Colitis. 2021;16(1):2–17. https://doi.org/10.1093/ecco-jcc/jjab178
9. Torres J, Bonovas S, Doherty G, Kucharzik T, Gisbert JP, Raine T, et al. ECCO guidelines on therapeutics in Crohn’s Disease: medical treatment. J Crohn’s Colitis. 2020;14(1):4–22. https://doi.org/10.1093/ecco-jcc/jjy120
10. Lorenzo D, Vullierme MP, Reborgs V. Antitumor necrosis factor therapy is effective for autoimmune pancreatitis type 2. Am J Gastroenterol. 2020;115(7):1133–4. https://doi.org/10.14309/aig.0000000000000668
11. Schneider A, Hirth M, Weiss C, Weidner P, Antoni C, Thomann A, et al. Prevalence of inflammatory bowel disease in alcoholic, non-alcoholic and autoimmune pancreatitis. Z Gastroenterol. 2018;56(5):469–78.
12. Almeida P, Almeida C, Gompertz M, Berger Z. Association between autoimmune pancreatitis and ulcerative colitis: a report of 12 patients. Rev Esp Enferm Dig. 2020;112(9):682–7. https://doi.org/10.17235/reed.2020.6677/2019
13. Kawa S, Okazaki K, Notohara K, Watanabe M, Shimosegawa T. Autoimmune pancreatitis complicated with inflammatory bowel disease and comparative study of type 1 and type 2 autoimmune pancreatitis. J Gastroenterol. 2015;50(7):805–15. https://doi.org/10.1007/s00535-014-1012-5
14. Kim JM, Hwang SW, Park SH, Song TJ, Kim MH, Lee HS, et al. Clinical course of ulcerative colitis patients who develop acute pancreatitis. World J Gastroenterol. 2017;23(19):3505–12. https://doi.org/10.1016/s1007-9327(17)31656-4
15. Maaser C, Sturm A, Vavricker SR, Kucharzik T, Fiorino G, Annese V, et al. ECCO-ESGAR guideline for diagnostic assessment in IBD Part 1: initial diagnosis, monitoring of known IBD, detection of complications. J Crohn’s Colitis. 2018;13(2):144–64K. https://doi.org/10.1093/ecco-jcc/jjy113
44. Barresi L, Tacelli M, Crino SF, Attili F, Petrone MC, De Nucci G, et al. Multicentric Italian survey on daily practice for autoimmune pancreatitis: clinical data, diagnosis, treatment, and evolution toward pancreatic insufficiency. United Eur Gastroenterol J. 2020;8(6):705–15. https://doi.org/10.1016/j.jpan.2020.07.026

45. Czakó L, Gyökeres T, Topa L, Sahin P, Takács T, Vincze A, et al. Autoimmune pancreatitis in Hungary: a multicenter nationwide study. Pancreatology: Off J Int Assoc Pancreatol. 2011;11(2):261–7. https://doi.org/10.1159/000327092

46. Kamisawa T, Chari ST, Giday SA, Kim MH, Chung JB, Lee KT, et al. Clinical profile of autoimmune pancreatitis and its histological subtypes: an international multicenter survey. Pancreas. 2011;40(6):809–14. https://doi.org/10.1097/mpa.0b013e3182258a15

47. Balasubramanian G, Sugumar A, Smyrk TC, Takahashi N, Clain JE, Gleeson FC, et al. Demystifying seronegative autoimmune pancreatitis. Pancreatology: Off J Int Assoc Pancreatol. 2012;12(4):289–94. https://doi.org/10.1016/j.pan.2012.05.003

48. de Pretis N, Vieceli F, Brandolese A, Brozzi L, Amodio A, Frulloni L. Autoimmune pancreatitis not otherwise specified (NOS): clinical features and outcomes of the forgotten type. Hepatobiliary Pancreat Dis Int: HBPD INT. 2019;18(6):576–9. https://doi.org/10.1016/j.hbpd.2019.05.010

49. Wilson A, Wang Q, Choi YH, Ponich T, Gregor JC, Chande N, et al. Pretreatment HLA-DQA1-HLADRB1 testing for the prevention of azathioprine-induced pancreatitis in inflammatory bowel disease: a prospective cohort study. Clin Transl Gastroenterol. 2021;12(4):e00332. https://doi.org/10.14309/ctg.0000000000000332

50. Zhang L, Chari S, Smyrk TC, Deshpande V, Klöppel G, Kojima M, et al. Autoimmune pancreatitis (AIP) type 1 and type 2: an international consensus study on histopathologic diagnostic criteria. Pancreas. 2011;40(8):1172–9. https://doi.org/10.1097/mpa.0b013e318233bec5

51. Chiabrando F, Lanzillotta M, Palumbo D, Pedica F, Caruso M, Capurso G, et al. Treating type 2 autoimmune pancreatitis with colchicine: a case series. Ann Intern Med. 2021;174(12):1775–1776. https://doi.org/10.7326/m21-0281

52. Matsubayashi H, Ishiwatari H, Imai K, Kishida Y, Ito S, Hotta K, et al. Steroid therapy and steroid response in autoimmune pancreatitis. Int J Mol Sci. 2019;21(1):257. https://doi.org/10.3390/ijms21010257

53. Nakamura A, Ozawa M, Watanabe T, Ito T, Muraki T, Hamano H, et al. Predictive factors for autoimmune pancreatitis relapse after 3 years of maintenance therapy. Pancreas. 2018;47(10):1337–43. https://doi.org/10.1097/mpa.0000000000001173

54. Miki M, Fujimori N, Oono T, Kawabe K, Ohno A, Matsumoto K, et al. Relapse patterns and predictors of IgG4-related diseases involved with autoimmune pancreatitis: a single-center retrospective study of 115 patients. J Dig Dis. 2019;20(3):152–8. https://doi.org/10.1111/1751-2980.12708

55. Vu Jasminovic M, Valente R, Maier P, von Beckerath V, Haas SL, Arnello U, et al. Diagnosis, treatment and long-term outcome of autoimmune pancreatitis in Sweden. Pancreatology: Off J Int Assoc Pancreatol. 2018;18(8):900–4. https://doi.org/10.1016/j.pan.2018.09.003

56. Salvatore S, Finazzi S, Barassi A, Verzelletti M, Tosi A, Melzi d’Eril GV, et al. Low fecal elastase: potentially related to transient small bowel damage resulting from enteric pathogens. J Pediatr Gastroenterol Nutr. 2003;36(3):392–6. https://doi.org/10.1097/00005176-200303000-00018

SUPPORTING INFORMATION
Additional supporting information can be found online in the Supporting Information section at the end of this article.